OBJECTIVE: To identify clinical and biochemical parameters that have good predictive value for identifying giant cell (temporal) @entity3468 (GCA) @entity1 who are at high or low risk of developing cranial @entity63 events. METHODS: In this multicenter study, records of @entity1 at 3 university hospitals in Barcelona were reviewed retrospectively. Two hundred consecutive @entity1 with biopsy-proven GCA were studied. RESULTS: Thirty-two @entity1 developed irreversible @entity63 . The duration of clinical symptoms before diagnosis was similar in @entity1 with and those without @entity63 events. @entity1 with @entity63 complications less frequently had @entity221 (18.8% versus 56.9%) and @entity353 (21.9% versus 62%) and more frequently had @entity1939 fugax (32.3% versus 6%) and transient @entity892 (15.6% versus 3.6%). @entity1 with @entity63 events had lower erythrocyte sedimentation rates (ESR) (82.7 mm/hour versus 104.4 mm/hour) and higher concentrations of hemoglobin (12.2 gm/dl versus 10.9 gm/dl) and albumin (37.4 gm/liter versus 32.7 gm/liter). Clinical inflammatory status and biologic inflammatory status were defined empirically (clinical: @entity221 and @entity353 ; biologic: ESR > or =85 mm/hour and hemoglobin < 11.0 gm/dl). @entity1 not showing a clinical and biologic inflammatory response were at high risk of developing @entity63 events (odds ratio [OR] 5, 95% confidence interval [95% CI] 2.05-12.2). The risk was greatly reduced among @entity1 with either a clinical (OR 0.177, 95% CI 0.052-0.605) or a biologic (OR 0.226, 95% CI 0.076-0.675) inflammatory reaction. No @entity1 with both a clinical and a biologic response developed @entity63 events. CONCLUSION: The presence of a strong acute-phase response defines a subgroup of @entity1 at very low risk of developing @entity63 . Our findings provide a rationale for testing less aggressive treatment schedules in these individuals. Conversely, a low inflammatory response and the presence of transient cranial @entity63 events provide a high risk of developing irreversible @entity63 complications and require a prompt therapeutic intervention.

Association between strong inflammatory response and low risk of developing visual loss and other @entity63 in giant cell (temporal) XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity63 :: ('MESH:D007511', 'Disease') :: ['cranial ischemic complications', 'ischemic'] @entity3468 :: ('MESH:D001167', 'Disease') :: ['arteritis'] @entity1939 :: ('MESH:D001766', 'Disease') :: ['amaurosis'] @entity892 :: ('MESH:D004172', 'Disease') :: ['diplopia'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever']
@entity3468 :: (MESH:D001167,Disease) :: ['arteritis']
